Skip to main content

Table 6 Dose escalation trials for stereotactic body radiotherapy for prostate cancer patients

From: A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer

Author Year n Dose and fractionation Follow-up Biochemical control Acute GU Acute GI Lage GU Late GI
Zelefsky 2019 136 32.5Gy - 40Gy in 5fx 3.5–5.9 years 5 years: 85–100% G2: 8.3–22.9%
≥G3: 0%
G2: 0–11.4%
≥G3: 0%
G2: 23.3–31.4%
≥G3: 0–2.9%
G2: 0%
≥G3: 0%
Hannan 2016 91 45Gy–50Gy in 5fx 66–74 months 5 years: 90.9–100% G2: 6.7–33.3%
≥G3: 0%
G2: 6.7–26.7%
≥G3: 0–3.2%
G2: 19.7–26.7%
≥G3: 0–6.7%
G2: 0–18%
≥G3: 0–9.9%
McBride 2012 45 36.25Gy–37.5Gy in 5fx 44.5 months 3 years: 100% G2: 19%
≥G3: 0%
G2: 7%
≥G3: 0%
G2: 17%
≥G3: 2%
G2: 7%
≥G3: 5%
Present study 27 32Gy–36Gy in 4fx 42 months 3 years: 90.3% G2: 0–33%
≥G3: 0%
G2: 0–11%
≥G3: 0%
G2: 0–11%
≥G3: 0%
G2: 0–11%
≥G3: 0%
  1. Abbreviations: GU Genitourinary toxicity, GI Gastrointestinal toxicity